OM:BIOG BBiotechs
Is BioGaia (OM:BIOG B) Quietly Redefining Its Global Strategy Through The Ewopharma Deal?
Earlier in 2026, BioGaia announced it had renewed and broadened its distribution agreement with regional partner Ewopharma, expanding access to its probiotic portfolio across more than 15 European countries.
This enlarged footprint with a long-standing regional distributor could be important for BioGaia’s efforts to scale its international presence through partnership-led growth.
We’ll now explore how the expanded Ewopharma distribution agreement may influence BioGaia’s investment narrative...